Biblio
Export 497 results:
Author [ Title] Type Year Filters: First Letter Of Keyword is N [Clear All Filters]
“Sex Influences the Accuracy of Subjective Memory Complaint Reporting in Older Adults.”, J Alzheimers Dis, vol. 61, no. 3, pp. 1163-1178, 2018.
, “Shortening of Saccades as a Possible Easy-to-Use Biomarker to Detect Risk of Alzheimer's Disease.”, J Alzheimers Dis, vol. 88, no. 2, pp. 609-618, 2022.
, “Social Cognition Deficits: The Key to Discriminate Behavioral Variant Frontotemporal Dementia from Alzheimer's Disease Regardless of Amnesia?”, J Alzheimers Dis, vol. 49, no. 4, pp. 1065-74, 2016.
, “Socioeconomic Status and Dementia Risk Among Intensive Care Unit Survivors: Using National Health Insurance Cohort in Korea.”, J Alzheimers Dis, vol. 97, no. 1, pp. 273-281, 2024.
, “Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration.”, Proc Natl Acad Sci U S A, vol. 108, no. 14, pp. 5819-24, 2011.
, “Soluble TREM2, Alzheimer's Disease Pathology, and Risk for Progression of Cerebral Small Vessel Disease: A Longitudinal Study.”, J Alzheimers Dis, vol. 92, no. 1, pp. 311-322, 2023.
, “SPARCL1 Accelerates Symptom Onset in Alzheimer's Disease and Influences Brain Structure and Function During Aging.”, J Alzheimers Dis, vol. 61, no. 1, pp. 401-414, 2018.
, “Spatial Memory Impairment is Associated with Intraneural Amyloid-β Immunoreactivity and Dysfunctional Arc Expression in the Hippocampal-CA3 Region of a Transgenic Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 1, pp. 69-79, 2016.
, “Spatial Memory Impairment is Associated with Intraneural Amyloid-β Immunoreactivity and Dysfunctional Arc Expression in the Hippocampal-CA3 Region of a Transgenic Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 1, pp. 69-79, 2016.
, “Spatial Navigation in Preclinical Alzheimer's Disease.”, J Alzheimers Dis, vol. 52, no. 1, pp. 77-90, 2016.
, “Specific Features of Subjective Cognitive Decline Predict Faster Conversion to Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 52, no. 1, pp. 271-81, 2016.
, “Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years.”, J Neuropathol Exp Neurol, vol. 70, no. 11, pp. 960-9, 2011.
, “Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years.”, J Neuropathol Exp Neurol, vol. 70, no. 11, pp. 960-9, 2011.
, “Strategies for improving memory: a randomized trial of memory groups for older people, including those with mild cognitive impairment.”, J Alzheimers Dis, vol. 49, no. 1, pp. 31-43, 2016.
, “Structural Connectivity Alterations Along the Alzheimer's Disease Continuum: Reproducibility Across Two Independent Samples and Correlation with Cerebrospinal Fluid Amyloid-β and Tau.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1575-1587, 2018.
, “STX, a Novel Membrane Estrogen Receptor Ligand, Protects Against Amyloid-β Toxicity.”, J Alzheimers Dis, vol. 51, no. 2, pp. 391-403, 2016.
, “STX, a Novel Membrane Estrogen Receptor Ligand, Protects Against Amyloid-β Toxicity.”, J Alzheimers Dis, vol. 51, no. 2, pp. 391-403, 2016.
, “Subjective Memory Complaints in APOEɛ4 Carriers are Associated with High Amyloid-β Burden.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1115-22, 2016.
, “A Super-Resolved View of the Alzheimer's Disease-Related Amyloidogenic Pathway in Hippocampal Neurons.”, J Alzheimers Dis, vol. 83, no. 2, pp. 833-852, 2021.
, “Synthetic Fragment of Receptor for Advanced Glycation End Products Prevents Memory Loss and Protects Brain Neurons in Olfactory Bulbectomized Mice.”, J Alzheimers Dis, vol. 61, no. 3, pp. 1061-1076, 2018.
, “T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 1, pp. 123-38, 2016.
, “Targretin Improves Cognitive and Biological Markers in a Patient with Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 2, pp. 271-6, 2016.
, “Tau and Amyloid Positron Emission Tomography Imaging Predict Driving Performance Among Older Adults with and without Preclinical Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 2, pp. 509-513, 2018.
, “Tauopathies: Mechanisms and Therapeutic Strategies.”, J Alzheimers Dis, vol. 61, no. 2, pp. 487-508, 2018.
, “Testamentary Capacity Assessment Tool (TCAT): A Brief Instrument for Patients with Dementia.”, J Alzheimers Dis, vol. 61, no. 3, pp. 985-994, 2018.
,